11 results about "Immuno suppression" patented technology

Provided herein are biomarkers that are useful in various aspects of treating and preventing complications and side effects associated with a disease or disorder, such as those associated with immune suppression, disruption of the gastrointestinal microbiome, infections (e.g., bloodstream infections), and / or GvHD, for example, in HSCT subjects. In some aspects, the biomarkers provided herein can be used in identifying a subject who is responding to a bacterial composition and / or subjects that are suitable for a treatment with a bacterial composition.

The application provides a recombinant oncolytic virus, a preparation method and a use thereof, wherein the recombinant oncolytic virus is rVSV M51R mIL27, in the application, by introducing IL-27 into the oncolytic vesicular stomatitis virus, on the one hand, the oncolytic vesicular stomatitis virus can be used as a delivery carrier to continuously express IL-27 in the tumor part, improve the effective concentration of IL-27 in the tumor microenvironment, and avoid systemic toxic side effects; on the other hand, IL-27 can synergize with the immune cell death induced by the oncolytic vesicular stomatitis virus to further enhance the antigen-specific T cell response and promote the transformation of tumor-infiltrating lymphocytes from an exhausted state to an effector state. Meanwhile, IL-27 helps to reshape the tumor immune microenvironment by inhibiting the immune suppressive cell population, thereby improving the overall immune response level. Therefore, the recombinant oncolytic virus provided in the application realizes multi-dimensional immune regulation of the tumor microenvironment through virus-mediated targeted delivery and continuous expression, thereby significantly improving the anti-tumor effect of the oncolytic virus therapy.

This invention belongs to the field of biotechnology, specifically relating to a biomarker for diagnosing immunosuppressive status in chronic tuberculosis and its application. The biomarker is arginase-1. This invention demonstrates that serum Arginase-1 levels are significantly elevated in the progression of chronic tuberculosis, and are significantly positively correlated with the enrichment ratio of myeloid-derived suppressor cells and the expression levels of T cell exhaustion markers. As a key effector molecule of MDSCs, high expression of Arginase-1 reflects abnormal arginine metabolism and T cell exhaustion caused by MDSC amplification, making it an ideal indicator for assessing the immunosuppressive microenvironment in chronic tuberculosis. Using the biomarker of this invention, serum samples can be detected by simple methods such as ELISA, enabling rapid diagnosis, stratification, and dynamic monitoring of the immune status of patients with chronic tuberculosis.

The invention relates to a combination therapy for treating liver cancer. The combination therapy mainly comprises combined application of L-selenomethionine and an immune checkpoint inhibitor (especially an anti-PD1 antibody). The composition can effectively inhibit tumor growth and enhance the tumor killing ability of an immune system. By reducing the number of tumor infiltration neutrophils and weakening the immunosuppression function of the neutrophils, the L-selenomethionine significantly improves the anti-tumor immune response. The invention provides a safe and effective treatment choice, the curative effect of the immune checkpoint inhibitor is remarkably improved, and a new treatment hope is brought to patients.

This invention discloses a time-series early warning method and system for avian adenovirus based on multi-source data fusion, specifically relating to the field of poultry infectious disease monitoring and early warning technology. It addresses the problem of systemic false positives caused by non-specific pathogen detection fluctuations being identified as pre-outbreak precursors. The method extracts pathogens exhibiting temporally mutually exclusive characteristics within the pre-outbreak window from multi-pathogen monitoring data as a set of candidate pathogenic incubation pathogens. It identifies conditional and independent incubation pathogens by combining environmental data with outbreak probability differences across different intervals. It identifies immunosuppressive pathogens based on the coupling phase desynchronization index between feed intake and time series and daily weight gain time series. It determines differentiated suppression weights based on pathogen incubation attributes and current environmental stress levels. After suppressing the multi-pathogen monitoring data, it inputs it along with environmental time series data into a time-series prediction model to output avian adenovirus outbreak early warning results, reducing false positives repeatedly triggered by the detection of conditional pathogens.

This invention provides a nanoformulation capable of enhancing the immune response to in situ tumor vaccines. The nanoformulation comprises zoledronic acid, all-trans retinoic acid, and metal ions. Preferably, the metal ion is a lanthanide metal, such as Gd. 3+ Preferred, zoledronic acid: Gd 3+ The mass ratio of all-trans retinoic acid is 4:1:5. The nano-formulation consists of zoledronic acid and Gd... 3+ Zol / Gd-NPs nanocoagulation polymers were formed by mixing in water. All-trans retinoic acid was dissolved in anhydrous ethanol to prepare albumin-encapsulated nanoparticles (A-NPs), which were then mixed with the Zol / Gd-NPs nanocoagulation polymers and sonicated to obtain the final product. These nanoparticles, on the one hand, can utilize zoledronic acid to eliminate macrophages, thereby reversing the inhibition of intratumoral dendritic cells (DCs) by the tumor immunosuppressive microenvironment; on the other hand, all-trans retinoic acid can significantly increase the expression of MHC-I and tumor antigens in tumor cells, thus ensuring the activation of CD8. + T cells can effectively recognize and kill tumors, generating a systemic anti-tumor immune response.

This invention discloses a BCG biomimetic vesicle and its application in the preparation of tumor nanovaccines, belonging to the field of tumor vaccines. The invention uses BCG strains or recombinant BCG strains as raw materials, and through a reduction-chelation-enzymatic hydrolysis synergistic cell disruption and high-pressure homogenization recombination process, produces BCG biomimetic vesicles and membrane-anchored tumor antigen genes. The BCG biomimetic vesicles prepared with BCG strains can efficiently induce BMDCs to establish training immune memory, while simultaneously promoting the differentiation of memory T cells and NK cell activation in lymph nodes, indirectly stimulating acquired immune responses, thereby inhibiting cervical cancer tumor growth. The BCG biomimetic vesicles prepared with recombinant BCG strains can synergistically activate lymph node acquired immunity and training immunity-mediated innate immunity, inhibiting the growth of HPV-related subcutaneous xenografts. This invention provides a candidate strategy for the immunotherapy of HPV-related tumors, with clear clinical application prospects and industrial value.

The application discloses application of an anti-CD150 antibody in preparation of a medicine, and belongs to the technical field of biological medicines. The medicine prepared based on the anti-CD150 antibody can act on CD150 positive B cells, release the immune suppression of the T cells, and thus realize treatment of B cell-mediated immune suppression related diseases.

Provided herein are biomarkers that are useful in various aspects of treating and preventing complications and side effects associated with a disease or disorder, such as those associated with immune suppression, disruption of the gastrointestinal microbiome, infections (e.g., bloodstream infections), and / or GvHD, for example, in HSCT subjects. In some aspects, the biomarkers provided herein can be used in identifying a subject who is responding to a bacterial composition and / or subjects that are suitable for a treatment with a bacterial composition.

This invention relates to a novel application of all-trans retinoic acid combined with a cyclooxygenase inhibitor in the treatment of prostate cancer. The all-trans retinoic acid is used to regulate gene expression and metabolic processes in tumor cells, promoting cell differentiation and tumor suppressor signaling pathways. The cyclooxygenase inhibitor is used to inhibit prostaglandin production induced by all-trans retinoic acid treatment. The cyclooxygenase inhibitor includes small molecule compounds that specifically inhibit / antagonize cyclooxygenase, interfering molecules that specifically interfere with cyclooxygenase gene expression, gene-editing reagents that specifically knock out the cyclooxygenase gene, reagents that downregulate / lose the function of cyclooxygenase, or antibodies that specifically bind to cyclooxygenase. The advantages are: it reveals that the combination of all-trans retinoic acid and a cyclooxygenase inhibitor reduces the immunosuppressive microenvironment in the tumor during prostate cancer treatment, thereby enhancing the tumor-suppressive effect and strengthening anti-tumor immunity.